<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">838</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2023-18-3-70-77</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSTIC OPPORTUNITIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ВОЗМОЖНОСТИ ДИАГНОСТИКИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical possibilities of flow cytometry in hodgkin’s lymphoma</article-title><trans-title-group xml:lang="ru"><trans-title>Клинические возможности проточной цитометрии при лимфоме Ходжкина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2359-0547</contrib-id><name-alternatives><name xml:lang="en"><surname>Abbasbeyli</surname><given-names>F. M.</given-names></name><name xml:lang="ru"><surname>Аббасбейли</surname><given-names>Ф. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Firuza Mazakhirovna Abbasbeyli</p><p>143081</p><p>111 1<sup>st</sup> Uspenskoe Shosse</p><p>Moscow region</p><p>Lapino</p></bio><bio xml:lang="ru"><p>Фируза Мазахировна Аббасбейли</p><p>143081</p><p>1-е Успенское шоссе, 111</p><p>Московская обл.</p><p>Лапино</p></bio><email>f.abbasbeyli@mcclinics.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4927-5585</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>143081</p><p>111 1<sup>st</sup> Uspenskoe Shosse</p><p>125284</p><p>3 2<sup>nd</sup> Botkinskiy Proezd</p><p>Moscow region</p><p>Lapino</p><p>Moscow</p></bio><bio xml:lang="ru"><p>143081</p><p>1-е Успенское шоссе, 111</p><p>125284</p><p>2-й Боткинский пр-д, 3</p><p>Московская обл.</p><p>Лапино</p><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>143081</p><p>111 1<sup>st</sup> Uspenskoe Shosse</p><p>119991</p><p>Build. 2, 8 Trubetskaya St.</p><p>Moscow region</p><p>Lapino</p><p>Moscow</p></bio><bio xml:lang="ru"><p>143081</p><p>1-е Успенское шоссе, 111</p><p>119991</p><p>ул. Трубецкая, 8, стр. 2</p><p>Московская обл.</p><p>Лапино</p><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5252-0436</contrib-id><name-alternatives><name xml:lang="en"><surname>Zibirov</surname><given-names>R. F.</given-names></name><name xml:lang="ru"><surname>Зибиров</surname><given-names>Р. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>249031</p><p>4 Koroleva St.</p><p>Obninsk</p></bio><bio xml:lang="ru"><p>249031</p><p>ул. Королева, 4</p><p>Обнинск</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grinevich</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Гриневич</surname><given-names>В. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125284</p><p>3 2<sup>nd</sup> Botkinskiy Proezd</p><p>Moscow</p></bio><bio xml:lang="ru"><p>125284</p><p>2-й Боткинский пр-д, 3</p><p>Москва</p></bio><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1266-1792</contrib-id><name-alternatives><name xml:lang="en"><surname>Mushkarina</surname><given-names>T. Yu.</given-names></name><name xml:lang="ru"><surname>Мушкарина</surname><given-names>Т. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>249031</p><p>4 Koroleva St.</p><p>Obninsk</p></bio><bio xml:lang="ru"><p>249031</p><p>ул. Королева, 4</p><p>Обнинск</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7229-2813</contrib-id><name-alternatives><name xml:lang="en"><surname>Melnikova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Мельникова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>249031</p><p>4 Koroleva St.</p><p>Obninsk</p></bio><bio xml:lang="ru"><p>249031</p><p>ул. Королева, 4</p><p>Обнинск</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1497-2436</contrib-id><name-alternatives><name xml:lang="en"><surname>Vernyuk</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Вернюк</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125284</p><p>3 2<sup>nd</sup> Botkinskiy Proezd</p><p>Moscow</p></bio><bio xml:lang="ru"><p>125284</p><p>2-й Боткинский пр-д, 3</p><p>Москва</p></bio><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9103-9688</contrib-id><name-alternatives><name xml:lang="en"><surname>Grivtsova</surname><given-names>L. Yu.</given-names></name><name xml:lang="ru"><surname>Гривцова</surname><given-names>Л. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>249031</p><p>4 Koroleva St.</p><p>Obninsk</p></bio><bio xml:lang="ru"><p>249031</p><p>ул. Королева, 4</p><p>Обнинск</p></bio><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Московский научно-исследовательский онкологический институт им. П. А. Герцена – филиал ФГБУ «Национальный&#13;
медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский&#13;
исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">P. A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Московский научно-исследовательский онкологический институт им. П. А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-09-13" publication-format="electronic"><day>13</day><month>09</month><year>2023</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>70</fpage><lpage>77</lpage><history><date date-type="received" iso-8601-date="2023-09-12"><day>12</day><month>09</month><year>2023</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/838">https://oncohematology.abvpress.ru/ongm/article/view/838</self-uri><abstract xml:lang="en"><p>   Hodgkin’s lymphoma (HL) is a unique lymphoma of b-cell origin, the tumor cells of which have lost the expression of main b-cell antigens. The standard immunophenotype of the tumor substrate, according to immunohistochemical studies, is characterized by the expression of such markers as CD15, CD30 and PAX-5, while tumor cells have a negative expression of CD3, CD19 and in most cases also CD20 and CD45 (or express this antigen rather weakly). The knowledge gained in recent years has increased the effectiveness of diagnosis, prognosis and treatment of LH. Flow cytometry, as a method of immunophenotyping in classical LH, was practically not used due to the difficulty of distinguishing single reed–sternberg–berezovsky tumor cells (RSB) and the tumor microenvironment (reactive background), which is very rich in cellular elements and is represented by T cells, B cells, eosinophils, histiocytes and plasma cells. However, in the recent past, several studies have successfully attempted to identify rsb cells using multiparameter flow cytometry during aspiration with a thin needle or biopsy of lymph node tissue to confirm or supplement immunohistochemical staining during primary diagnosis. Taking into account the very characteristic immunophenotype of RSB cells, the flow cytometry may become an additional diagnostic method of classical LH in the future. In this review, we summarize the data on the possibility of using the flow cytometry as an additional clinical diagnostic option in the primary diagnosis of classical LH.</p></abstract><trans-abstract xml:lang="ru"><p>   Лимфома Ходжкина (ЛХ) – уникальная лимфома В-клеточного происхождения, опухолевые клетки которой утратили экспрессию основных В-клеточных антигенов. По данным иммуногистохимического исследования стандартный иммунофенотип опухолевого субстрата характеризуется экспрессией таких маркеров, как CD15, CD30 и PAX-5, при этом опухолевые клетки имеют отрицательную экспрессию CD3, CD19 и в большинстве случаев также CD20 и CD45 (или экспрессируют этот антиген достаточно слабо). С помощью знаний, полученных за последние годы, удалось повысить эффективность диагностики, прогнозирования и лечения ЛХ. Проточная цитометрия как метод иммунофенотипирования при классической ЛХ практически не применялся из-за трудности разграничения единичных опухолевых клеток Березовского–Рид–Штернберга (БРШ) и опухолевого микроокружения (реактивного фона), которое очень богато клеточными элементами и представлено Т-клетками, В-клетками, эозинофилами, гистиоцитами и плазматическими клетками. Недавно в нескольких исследованиях были предприняты успешные попытки выявить клетки БРШ с использованием многопараметровой проточной цитометрии при аспирации тонкой иглой или биопсии ткани лимфатических узлов для подтверждения или дополнения результатов иммуногистохимического исследования при первичной диагностике. С учетом весьма характерного иммунофенотипа клеток БРШ проточная цитометрия в дальнейшем может стать дополнительным диагностическим методом классической ЛХ. В настоящем обзоре мы суммируем данные относительно возможности использования метода проточной цитометрии как дополнительной клинической первичной диагностической опции при классической ЛХ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Hodgkin’s lymphoma</kwd><kwd>reed–sternberg–berezovsky tumor cell</kwd><kwd>flow cytometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>клетка Березовского–Рид–Штернберга</kwd><kwd>проточная цитометрия</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was performed without external funding</funding-statement><funding-statement xml:lang="ru">Работа выполнена без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hodgkin. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832;17:68–114. URL: https://pubmed.ncbi.nlm.nih.gov/20895597/</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wilks S. Cases of enlargement of the lymphatics glands and spleen (or, Hodgkin’s disease) with remarks. Guys Hosp Rep 1856;11:56–67.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;19;127(20):2375–90. DOI: 10.1182/blood-2016-01-643569</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cree I.A. The WHO Classification of Haematolymphoid Tumours. Leukemia 2022;36(7):1701–2. DOI: 10.1038/s41375-022-01625-x</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chang K.C., Khen N.T., Jones D., Su I.J. Epstein–Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol 2005;36(7):747–55. DOI: 10.1016/j.humpath.2005.05.003</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Gemici A., Aydogdu I., Terzi H. et al. Nodular lymphocyte predominant Hodgkin’s lymphoma in daily practice: A multicenter experience. Hematol Oncol 2018;36(1):116–20. DOI: 10.1002/hon.2460</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shankar A.G., Roques G., Kirkwood A.A. et al. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome – a report from the SFCE &amp; CCLG groups. Br J Haematol 2017;177(1):106–15. DOI: 10.1111/bjh.14518</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fromm J.R., Thomas A., Wood B.L. Characterization and purification of neoplastic cells of nodular lymphocyte predominant Hodgkin lymphoma from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Pathol 2017;187(2):304–17. DOI: 10.1016/j.ajpath.2016.10.007</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Savage K.J., Mottok A., Fanale M. Nodular lympho­ cytepredominant Hodgkin lymphoma. Semin Hematol 2016;53(3):190–202. DOI: 10.1053/j.seminhematol.2016.05.009</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Goel A., Fan W., Patel A.A. Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk 2014;14(4):261–70. DOI: 10.1016/j.clml.2014.01.006</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sohani A.R., Jaffe E.S., Harris N.L. et al. Nodular lymphocyte predominant Hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T­cell lymphoma. Am J Surg Pathol 2011;35(11):1666–78. DOI: 10.1097/PAS.0b013e31822832de</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dorfman D.M., Hwang E.S., Shahsafaei A., Glimcher L.H. T­bet, a T cell­associated transcription factor, is expressed in Hodgkin’s lymphoma. Hum Pathol 2005;36(1):10–5. DOI: 10.1016/j.humpath.2004.10.006</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Taylor C.R. Hodgkin’s disease is a non­Hodgkin lymphoma. Hum Pathol 2005;36(1):1–4. DOI: 10.1016/j.humpath.2004.12.006</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Visser L., Rutgers B., Diepstra A. et al. Characterization of the microenvironment of nodular lymphocyte predominant Hodgkin lymphoma. Int J Mol Sci 2016;17(12):2127. DOI: 10.3390/ijms17122127</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nathwani B.N., Vornanen M., Winkelmann R. et al. Intranodular clusters of activated cells with T follicular helper phenotype in nodular lymphocyte predominant Hodgkin lymphoma: a pilot study of 32 cases from Finland. Hum Pathol 2013;44(9):1737–46. DOI: 10.1016/j.humpath.2013.02.010</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sharma S., Dey P., Mitra S. et al. Nodular sclerosis classical Hodgkin lymphoma grade 2: a diagnostic challenge to the cytopathologists. Cancer Cytopathol 2017;125(2):104–13. DOI: 10.1002/cncy.21799</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Marcheselli R., Bari A., Tadmor T. et al. Neutrophil­lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol 2017;35(4):561–6. DOI: 10.1002/hon.2359</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ansell S.M. Hodgkin lymphoma: 2016 update on diagnosis, risk stratification, and management. Am J Hematol 2016;91(4):434–42. DOI: 10.1002/ajh.24272</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Cheng C.L., O’Connor S. T cell­-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach. J Clin Pathol 2017;70(3):187–201. DOI: 10.1136/jclinpath-2016-204065</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Scheidt V., Hansmann M.L., Schuhmacher B. et al. Atypical variants of nodular lymphocyte­predominant Hodgkin lymphoma show low microvessel density and vessels of distention type. Hum Pathol 2017;60:129–36. DOI: 10.1016/j.humpath.2016.10.008</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Carbone A., Gloghini A., Caruso A. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. Int J Cancer 2017;140(6):1233–45. DOI: 10.1002/ijc.30473</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Swerdlow S.H. Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. Mod Pathol 2013;26(Suppl 1):S1–14. DOI: 10.1038/modpathol.2012.177</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Campo E., Swerdlow S.H., Harris N.L. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019–32. DOI: 10.1182/blood-2011-01-293050</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Grivtsova L.Yu., Mushkarina T.Yu., Lunin V.V., Zeynalova P.A. Flow cytometry in the diagnosis of plasma cell tumors and assessment of minimal residual disease. Onkogematologiya = Oncohematology 2021;16(3):16–25. (In Russ.). DOI: 10.17650/1818-8346-2021-16-3-16-25</mixed-citation><mixed-citation xml:lang="ru">Гривцова Л.Ю., Мушкарина Т.Ю., Лунин В.В., Зейналова П.А. Проточная цитометрия при диагностике плазмоклеточных опухолей и оценке минимальной остаточной болезни. Онкогематология 2021;16(3):16–25. DOI: 10.17650/1818-8346-2021-16-3-16-25</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Chernysheva O.A., Grivtsova L.Yu., Serebryakova I.N. et al. Diagnosis of acute lymphoblastic leukemia originating from T-­lineage precursors and approaches to minimal residual disease monitoring. Klinicheskaya onkogematologiya = Clinical Oncohematology 2019;12(1):79–85. (In Russ.). URL: https://bloodjournal.ru/wp-content/uploads/2018/12/11.pdf?ysclid=lmg6bdgnq985487735</mixed-citation><mixed-citation xml:lang="ru">Чернышева О.А., Гривцова Л.Ю., Серебрякова И.Н. и др. Диагностика острых лимфобластных лейкозов из Т­-линейных предшественников и подходы к мониторингу минимальной остаточной болезни. Клиническая онкогематология 2019;12(1):79–85. URL: https://bloodjournal.ru/wp-content/uploads/2018/12/11.pdf?ysclid=lmg6bdgnq985487735</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Beznos O.A., Grivtsova L.Yu., Tupitsyn N.N. Optimization of flow cytometry protocols for detection of minimal residual disease in acute lymphoblastic leukemia. Meditsinskiy alfavit = Medical Alphabet 2018;1(5):36–9. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Безнос О.А., Гривцова Л.Ю., Тупицын Н.Н. Оптимизация проточно­цитометрических протоколов детекции минимальной остаточной болезни при острых лимфобластных лейкозах. Ме­lицинский алфавит 2018;1(5):36–9.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Grivtsova L.Yu., Kupryshina N.N., Frenkel M.A. et al. Diagnosis and immunophenotypic features of blast cells in acute myeloid leukemia: pan­myeloid and linear­nonrestricted antigens. Meditsinskiy alfavit = Medical Alphabet 2017;4(28):17–21. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Гривцова Л.Ю., Купрышина Н.А., Френкель М.А. и др. Диагностика и иммунофенотипические особенности бластных кле­ток при острых миелоидных лейкозах: экспрессия пан­миело­идных и линейно­нерестриктированных антигенов. Медицинский алфавит 2017;4(28):17–21.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Galtseva I.V., Smirnova S.Yu., Parovichnikova E.N. Methodological aspects of the detection of minimal residual disease in patients with acute leukemia. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2022;67(1):108–20. (In Russ.). DOI: 10.35754/0234-5730-2022-67-1-108-120</mixed-citation><mixed-citation xml:lang="ru">Гальцева И.В., Смирнова С.Ю., Паровичникова Е.Н. Методи­xеские аспекты детекции минимальной остаточной болезни у больных острыми лейкозами. Гематология и трансфузиоло­гия 2022;67(1):108–20. DOI: 10.35754/0234-5730-2022-67-1-108-120</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Galtseva I.V., Davydova Yu.O., Parovichnikova E.N. et al. Minimal residual disease and b­cell subpopulation monitoring in acute B­lymphoblastic leukaemia patients treated on rall­2016 protocol. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2021;66(2):192–205. (In Russ.). DOI: 10.35754/0234-5730-2021-66-2-192-205</mixed-citation><mixed-citation xml:lang="ru">Гальцева И.В., Давыдова Ю.О., Паровичникова Е.Н. и др. Мониторинг минимальной остаточной болезни и B­-клеточных субпопуляций у больных острым B­-лимфобластным лейкозом, леченных по протоколу «ОЛЛ­2016». Гематология трансфузиология 2021;66(2):192–205. DOI: 10.35754/0234-5730-2021-66-2-192-205</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><mixed-citation>Fromm J.R., Kussick S.J., Wood B.L. Identification and puri­fication of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol 2006;126(5):764–80. DOI: 10.1309/7371-XK6F-6P74-74XX</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Fromm J.R., Thomas A., Wood B.L. Flow cytometry can diagnose classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity. Am J Clin Pathol 2009;131(3):322–32. DOI: 10.1309/AJCPW3UN9DYLDSPB</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Fromm J.R., Wood B.L. A six­color flow cytometry assay for immunophenotyping classical Hodgkin lymphoma in lymph nodes. Am J Clin Pathol 2014;141(3):388–96. DOI: 10.1309/AJCP0Q1SVOXBHMAM</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Wu D., Wood B.L., Dorer R., Fromm J.R. Utility of flow cytometry for immunophenotyping double­hit lymphomas. Cytometry B Clin Cytom 2013;84(6):398. DOI: 10.1002/cyto.b.21117</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wu D., Wood B.L., Fromm J.R. Flow cytometry for non Hodgkin and classical Hodgkin lymphoma. Methods Mol Biol 2013;971:27–47. DOI: 10.1007/978-1-62703-269-8_2</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Engert A., Plütschow A., Eich H.T. et al. Reduced treatment intensity in patients with early­stage Hodgkin’s lymphoma. N Engl J Med 2010;363(7):640–52. DOI: 10.1056/NEJMoa1000067</mixed-citation></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Abbasbeyli F.M., Fedenko A.A., Zeynalova P.A. et al. Identification of Reed–Berezovsky–Sternberg cells in lymphatic nodes in classic Hodgkin’s lymphoma by flow cytometry: a clinical case series. Al’manah klinicheskoy meditsiny = Almanac of Clinical Medicine 2023;51(2):134–42. (In Russ.). DOI: 10.18786/2072-0505-2023-51-015</mixed-citation><mixed-citation xml:lang="ru">Аббасбейли Ф.М., Феденко А.А., Зейналова П.А. и др. Выявление клеток Березовского–Рид–Штернберга в лимфатических узлах при классической лимфоме Ходжкина методом проточной цитометрии. Альманах клинической медицины 2023;51(2):134–42. DOI: 10.18786/2072-0505-2023-51-015</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><mixed-citation>Jiang M., Bennani N.N., Feldman A.L. Lymphoma classification update: B­cell non­Hodgkin lymphomas. Expert Rev Hematol 2017;10(5):405–15. DOI: 10.1080/17474086.2017.1318053</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Roshal M., Wood B.L., Fromm J.R. Flow cytometric detection of the classical Hodgkin lymphoma: clinical and research applications. Adv Hematol 2011;2011:387034. DOI: 10.1155/2011/387034</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kelly K.M., Sposto R., Hutchinson R. et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high­risk Hodgkin lymphoma: a report from the Children’s Oncology Group. Blood 2011;117(9):2596–603. DOI: 10.1182/blood-2010-05-285379</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Bosler D.S., Douglas­Nikitin V.K., Harris V.N., Smith M.D. Detection of T­regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom 2008;74(4):227–35. DOI: 10.1002/cyto.b.20407</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Hudnall S.D., Betancourt E., Barnhart E., Patel J. Comparative flow immunophenotypic features of the inflammatory infiltrates of Hodgkin lymphoma and lymphoid hyperplasia. Cytometry B Clin Cytom 2008;74(1):1–8. DOI: 10.1002/cyto.b.20376</mixed-citation></ref></ref-list></back></article>
